Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Opthea Ltd (OPT.AX)

Opthea Ltd (OPT.AX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [ASX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Opthea Ltd C/ Prime Company Compliance 505 Little Collins Street, Level 9 Melbourne VIC 3000 AUS

https://www.opthea.com P: +61 398260399 F: +61 398240083

Sector:

N/A

INDUSTRY GROUPING:

N/A

Description:

Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.

Key Statistics

Overview:

Market Capitalization, $K 738,751
Shares Outstanding, K 1,367,978
Annual Sales, $ 25 K
Annual Net Income, $ -162,791 K
% of Institutional Shareholders 7.28%

Growth:

1-Year Return -5.51%
3-Year Return -36.51%
5-Year Return -61.04%
5-Year Revenue Growth -15.80%

Per-Share Information:

Next Earnings Date N/A
Earnings Per Share ttm -0.13
Most Recent Dividend 0.102 on 10/11/04
Next Ex-Dividends Date 10/11/04
Dividend Payable Date 10/29/04
Dividend Payout Ratio 0.00%
Most Recent Split 1-1 on 08/15/97

OPT.AX Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Return-on-Equity % N/A
Return-on-Assets % -132.57%
Profit Margin % -651,164.00%
Debt/Equity N/A
Price/Sales 4,246.08
Price/Book N/A
Book Value/Share -0.21
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar